Does OBINUTUZUMAB Cause Myelosuppression? 459 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 459 reports of Myelosuppression have been filed in association with OBINUTUZUMAB (Gazyva). This represents 3.2% of all adverse event reports for OBINUTUZUMAB.
459
Reports of Myelosuppression with OBINUTUZUMAB
3.2%
of all OBINUTUZUMAB reports
25
Deaths
160
Hospitalizations
How Dangerous Is Myelosuppression From OBINUTUZUMAB?
Of the 459 reports, 25 (5.4%) resulted in death, 160 (34.9%) required hospitalization, and 17 (3.7%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 459 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which OBINUTUZUMAB Alternatives Have Lower Myelosuppression Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE